Accessibility StatementSkip Navigation PHILADELPHIA, Nov. 17, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, ...

Core Insights - Biotech investing is becoming increasingly attractive due to anticipated rate cuts in late 2025 and a more favorable regulatory environment, positioning it as a smart investment option for the end of the year [1] - The Future Health Care Equity ETF (GDOC) is highlighted as a strong buy signal, actively investing in companies driving global biotech innovation [2] Investment Performance - GDOC charges a fee of 75 basis points and focuses on sectors such as genomics, digital healthcare, and precision medicine [2] - The ETF has shown significant performance, returning 16% over the last three months and 9.4% over the last month, outperforming its category average during that timeframe [2] - The performance spike aligns with recent Federal Reserve rate cuts, contributing to GDOC's strong buy signal [2] Technical Indicators - As of November 14, GDOC's price has surpassed both its 50-day and 200-day simple moving averages (SMAs), indicating strong momentum [2] - The ETF's active management approach allows for investments in futures, forwards, and other options, enhancing overall exposure [2] Market Context - Investors may be concerned about concentration risk in megacap tech but can still benefit from AI innovations in biotech through ETFs like GDOC [2] - The decline in debt service costs may provide additional advantages for investors considering biotech investments [2]

Market Overview - The US equity market experienced a rally in the third quarter of 2025, with the S&P 500 Index increasing by 8.12% [1] - Bonds also performed well, with the Bloomberg U.S. Aggregate Bond Index rising by 2.03% during the same period [1] Performance Analysis - The composite return for the quarter was 7.22% gross of fees and 7.10% net of fees, which underperformed the S&P 500 Index's gain of 8.12% [1] - The underperformance of the strategy was attributed to security selection [1] Company Spotlight: Adaptive Biotechnologies Corporation - Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is highlighted as a key stock, with a one-month return of -20.92% and a 52-week gain of 201.28% [2] - As of November 14, 2025, the stock closed at $14.10 per share, with a market capitalization of $2.159 billion [2] Performance Contribution - Adaptive Biotechnologies contributed positively to performance in the third quarter, driven by momentum in its minimal residual disease (MRD) testing business, particularly the clonoSEQ test [3] - The company reported better-than-expected earnings and raised its full-year guidance, with average selling price increases complementing accelerating volume growth [3] Hedge Fund Interest - Adaptive Biotechnologies was held by 26 hedge fund portfolios at the end of the second quarter, a slight decrease from 27 in the previous quarter [4] - While the company shows potential, there is a belief that certain AI stocks may offer greater upside potential with less downside risk [4]

Core Insights - Kraig Biocraft Laboratories (KBLB) is positioned to capitalize on the growing demand for high-performance spider silk materials, with significant advancements in its production capabilities and commercialization efforts [1][8][12] Production and Technology Advancements - The 2025 production program will feature the large-scale deployment of the BAM-1 Alpha recombinant silk platform, which is expected to attract interest from luxury brands, defense contractors, and biomedical firms [2][4] - The BAM-1 Alpha platform enhances production efficiency by utilizing genetically engineered silkworms, addressing the challenges of traditional spider farming [3][12] - Recent developments include a 20-30% production increase due to selective breeding updates and the completion of a parallel two-facility cycle, which enhances silk quality and volume [6][10] Market Positioning and Strategic Timing - Kraig Labs is on track to deliver initial quantities of recombinant spider silk fibers to partners before year-end, targeting performance textile, defense, and luxury markets [5][11] - The global technical textiles market is projected to reach $200 billion by 2030, with a compound annual growth rate (CAGR) of 5.2%, providing a favorable environment for KBLB's commercialization efforts [8] - The company's strategic momentum heading into 2026 is bolstered by its ability to meet year-end supply availability for potential customers in luxury apparel and specialty materials [9][11] Supply Chain and Scalability - Kraig Labs has strengthened its supply chains with the establishment of a new diapausing system and a Cambodian operations license, facilitating potential deliveries to European luxury partners [7] - The hybridized silkworm technology has demonstrated repeatable scalability, crucial for consistent supply and commercial delivery of spider silk materials [7][12] - If production remains on schedule, KBLB could enter 2026 with tangible proof of scalability, marking a significant inflection point for the company and its technology [13]

Johnson & Johnson agreed to buy the cancer treatment biotech Halda Therapeutics in a $3.05 billion cash deal, the companies said in a statement Monday. https://t.co/zaDJ9vkfHf ...

Group 1 - Top Wall Street analysts have changed their outlook on several prominent stocks, indicating a shift in market sentiment [1] - The article suggests that investors should consider buying ANRO stock based on analysts' recommendations [1]

ADIA Nutrition Inc. Requests SIC Code Update to 2836 (Biological Products) with SEC and OTC MarketsNovember 17, 2025 8:00 AM EST | Source: Adia Nutrition Inc.Winter Park, Florida--(Newsfile Corp. - November 17, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, today announced it has filed with the SEC to update its Standard Industrial Classification (SIC) code from 2834 (Pharmaceutical Preparations) to 2836 (Biological Products, Except Diagnostic) and with OTC Mark ...

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that Michael Newman, Ph.D., Founder and Chief Scientific Officer, will present at the 3rd Donor Selection & Cell Source Summit, taking place November 19–20, 2025, in San Diego, California. Dr. Newman’s presentation, titled, “Creating Super Donor Cells Post-Donation ...

Core Viewpoint - ProPhase Labs, Inc. is urging shareholders to vote in favor of all proposals at the upcoming Special Meeting to support the company's long-term strategic vision and compliance with Nasdaq listing requirements [3][4]. Group 1: Special Meeting Details - The Special Meeting of Stockholders is scheduled for November 24, 2025, at 10:00 a.m. ET, for shareholders of record as of October 20, 2025 [1]. - Shareholders are encouraged to vote their shares before the proxy voting deadline of 11:59 p.m. ET on November 23, 2025 [2]. Group 2: Importance of Voting - Voting FOR all proposals will enable ProPhase Labs to advance its strategic initiatives and maintain compliance with Nasdaq requirements [3]. - Not voting is equivalent to voting against the proposals, which could limit the company's strategic options and hinder its ability to capitalize on new opportunities [4]. Group 3: Company Overview - ProPhase Labs, Inc. is a biotech and consumer products company focused on innovative healthcare solutions, including Whole Genome Sequencing and diagnostic tests [6]. - The company aims to build a healthier world through innovation and actionable insights, with a commitment to executional excellence and smart diversification [6].

Core Insights - 4D Molecular Therapeutics has appointed Kristian Humer as Chief Financial Officer to lead financial strategy and operations [1][2][3] - The company is advancing multiple Phase 3 programs and preparing for commercial readiness, indicating a critical stage in its development [3][4] Company Overview - 4D Molecular Therapeutics is a late-stage biotechnology company focused on durable and disease-targeted therapeutics, aiming to transform treatment paradigms [1][4] - The lead product candidate, 4D-150, targets blinding retinal vascular diseases and is currently in Phase 3 development for wet age-related macular degeneration and diabetic macular edema [4] - The second product candidate, 4D-710, is a genetic medicine for cystic fibrosis, demonstrating successful delivery of the CFTR transgene [4] Leadership Background - Kristian Humer brings over 20 years of experience in corporate finance and healthcare investment banking, having held senior roles at Citi and served as CFO for other publicly traded companies [2][3] - His expertise is expected to enhance 4DMT's long-term growth and value creation for patients and shareholders [3]